Last reviewed · How we verify
NanoDOX® Hydrogel
At a glance
| Generic name | NanoDOX® Hydrogel |
|---|---|
| Also known as | Doxycycline application |
| Sponsor | Massachusetts General Hospital |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
- eczema flare-requiring steroid systemic treatment
- upper respiratory infection
Key clinical trials
- Investigation of Laser Assisted Drug Delivery of NanoDOX® (PHASE2)
- Topical NanoDox® for Atopic Dermatitis (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NanoDOX® Hydrogel CI brief — competitive landscape report
- NanoDOX® Hydrogel updates RSS · CI watch RSS
- Massachusetts General Hospital portfolio CI